Compare CRSP & IEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | IEP |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.7B |
| IPO Year | 2016 | 1994 |
| Metric | CRSP | IEP |
|---|---|---|
| Price | $50.34 | $4.85 |
| Analyst Decision | Buy | |
| Analyst Count | 23 | 0 |
| Target Price | ★ $85.42 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 11-02-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 42.10% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $289,590,000.00 | ★ $9,658,000,000.00 |
| Revenue This Year | $910.97 | $1.70 |
| Revenue Next Year | $277.83 | $6.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $44.12 | $4.73 |
| 52 Week High | $63.45 | $9.10 |
| Indicator | CRSP | IEP |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 19.96 |
| Support Level | $50.02 | N/A |
| Resistance Level | $60.68 | $7.80 |
| Average True Range (ATR) | 2.44 | 0.27 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 36.10 | 5.95 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Icahn Enterprises LP provides diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.